| Note |
For graduate student John R., lying down to sleep was a real eye-opener. Meet John R., age 33. B.A., cum laude. Ph.D. in the making. But until recently, it looked as if he might not make it. His problem: insomnia. Clinically confirmed. Unwanted wakefulness every night. It was wreaking havoc with his studies. And with his personal relationships, too. Quaalude-300 (methaqualone) helped solve John R.'s problem…but under rather unusual circumstances. John R. volunteer to participate…along with nine other confirmed insomniacs…in a sleep study of experimental design, single blind, to evaluate Quaalude-300 against a placebo. Sequentially, there were three placebo nights, followed by three drug nights, followed by four placebo nights. EEG recordings were obtained continuously from 2300 to 0600 hours. He returned for a second period of 10 days three weeks later. Goldstein, et al., reported that two statistically significant benefits of Quaalude-300 were apparent in this particular study. Time needed for the insomniacs to fall asleep was reduced. Intermittent periods of wakefulness…so common among insomniacs…were shorter when Quaalude was used. Other clinical studies, plus experience in medical practice throughout the world, have established the therapeutic value of non-barbiturate methaqualone: Quaalude can induce sleep in 10 to 30 minutes; it usually helps produce 6 to 8 hours of restful sleep' Quaalude patients usually awaken easily and without evidence of "hangover". Side effects reported have been mild, transient, and have often proved to be statistically insignificant when compared to placebo effects. Psychological dependence occasionally occurs, physical dependence rarely reported. (See Brief Summary of Prescribing Information.) Maybe your patients can benefit as John R., did by your prescribing Quaalude. |
